Japanese Government Pays Family for Death Tied to COVID Shot
On July 25, 2022, a committee of Japan’s Ministry of Health, Labor and Welfare announced that it would provide a lump-sum death benefit of ¥44.2 million ($324,000), plus an additional ¥212,000 for funeral expenses, to the family of an elderly woman who died shortly after receiving a COVID-19 shot. The committee determined there was a […]
Nuvaxovid Offered as Alternative to mRNA Shots
For a virus (SARS-CoV-2) that many scientists and public health officials have maintained originated in a bat and accidently crossed over into humans, leading to the COVID-19 pandemic, it is odd that there does not appear to be much concern about producing vaccines that use genetic material from animals. You would think that this would […]
VAERS Data Reveal Serious Adverse Event Reports in Babies After mRNA COVID Shots
On June 15, 2022, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) advised the FDA to grant an Emergency Use Authorization (EUA) for Moderna/NIAID and Pfizer/BioNTech’s mRNA COVID-19 biologics be given to infants and children under age five and as young as six months old. With […]
Research Confirms Menstrual Cycle Bleeding Changes After COVID Shot
Last week, University of Illinois researchers published a study funded by the National Institutes of Health (NIH) in the journal Science Advances on menstrual cycle bleeding changes after COVID shots. The study featured a web-based survey of almost 40,000 individuals and found 42 percent of those who were menstruating reported unexpected heavy bleeding after receiving […]
FDA Grants EUA for Novavax’s COVID Vaccine
Opinion | On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax to distribute its experimental two-dose NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine for use by adults. The decision was expected, given the favorable recommendation by the FDA’s Vaccines and Related Biological Products Advisory […]
‘COVID-19 Rebound’ May Be Worse Than Initial COVID Illness
On May 24, 2022, the U.S. Centers for Disease Control and Prevention (CDC) issued a health advisory to health care providers, public health departments and the general public regarding Pfizer’s antiviral drug Paxlovid, designed to treat symptoms of COVID-19. The advisory warns that some people who take Paxlovid may experience a recurrence of COVID symptoms […]
